Last reviewed · How we verify
Brentuximab Vedotin - induction
Brentuximab vedotin is a monoclonal antibody-drug conjugate that targets CD30, a protein often found on the surface of Hodgkin lymphoma and anaplastic large cell lymphoma cells.
Brentuximab vedotin is a monoclonal antibody-drug conjugate that targets CD30, a protein often found on the surface of Hodgkin lymphoma and anaplastic large cell lymphoma cells. Used for Hodgkin lymphoma, Anaplastic large cell lymphoma.
At a glance
| Generic name | Brentuximab Vedotin - induction |
|---|---|
| Also known as | Adcetris |
| Sponsor | The Lymphoma Academic Research Organisation |
| Drug class | Monoclonal antibody-drug conjugate |
| Target | CD30 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
It works by binding to CD30 and delivering a toxic agent, monomethyl auristatin E, into the cell, leading to cell death. This targeted approach helps minimize damage to healthy cells.
Approved indications
- Hodgkin lymphoma
- Anaplastic large cell lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Fatigue
- Nausea
Key clinical trials
- Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant. (PHASE2)
- Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL (PHASE1)
- Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma (PHASE2)
- Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL (PHASE2)
- Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma (PHASE2)
- Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma (EARLY_PHASE1)
- Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine (PHASE2)
- Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: